FDA ApprovedUnited States
New Daily Pill for Moderate-to-Severe Psoriasis (Ages 12+)
Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis — 12 and older, at least 40 kg
The FDA labelled a once-daily 200 mg oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis in people 12 and older who weigh at least 40 kg and…
The FDA labelled a once-daily 200 mg oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis in…